Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) ended Friday session in green amid volatile trading. The shares closed up +0.013 points or 5.44% at $0.250 with 3.13 million shares getting traded. Post opening the session at $0.25, the shares hit an intraday low of $0.23 and an intraday high of $0.26 and the price vacillated in this range throughout the day. The company has a market cap of $52.20 million and the numbers of outstanding shares have been calculated to be 195.19 million shares.
Cytori Therapeutics Inc (CYTX) on May 6, 2016 announced the presentation of six and twelve month data from the ATHENA Trials at the annual meeting of The Society for Cardiovascular Angiography and Interventions. The ATHENA trials are two prospective, randomized (2:1, active : placebo), double-blind, controlled, parallel group trials (ATHENA and ATHENA II) each assessing Cytori Cell Therapy® [ATHENA: 20 million cells, 28 patients; ATHENA II: 40 million cells, 3 patients]. The objective of the ATHENA program was assessment of safety and feasibility of Cytori Cell Therapy using the Celution® System automated on-site manufacturing of the cellular therapeutic and intramyocardial delivery for treatment of chronic ischemic heart disease with left heart failure.
On the treatment day, patients underwent fat harvest via small volume lipoharvest followed by cell processing, electromechanical mapping of the left ventricle with subsequent injection of cells (or placebo) into viable myocardium intramyocardial.
A total of 31 patients (17 Cytori Cell Therapy, 14 placebo) were randomized prior to termination of enrollment, with 28 patients having 6 month or longer follow-up data. Trial enrollment was terminated prematurely due to the prolonged period of enrollment required. Enrollment was prolonged due to challenges in identifying suitable patients who met all inclusion/exclusion criteria and two trial enrollment delays related to safety reviews during the trial. ATHENA and ATHENA II trial data were combined for analyses.
Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) ended Friday session in green amid volatile trading. The shares closed up +0.03 points or 2.24% at $1.37 with 899,674.00 shares getting traded. Post opening the session at $1.34, the shares hit an intraday low of $1.30 and an intraday high of $1.40 and the price vacillated in this range throughout the day. The company has a market cap of $169.91 million and the numbers of outstanding shares have been calculated to be 121.31 million shares.
Idera Pharmaceuticals Inc (IDRA) on May 05, 2016 announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.
The company will host a conference call and live audio webcast at 5:00 P.M. Eastern Time on the same day. During the conference call, Idera management will discuss the company’s recent progress and provide a clinical update from the ongoing Phase 1/2 trial of IMO-8400 in Waldenstrom’s Macroglobulinemia.
Live audio webcast of Idera’s presentations will be accessible in the Investors section of Idera’s website at http://www.iderapharma.com. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). Archived versions will also be available on the Company’s website after the event for 90 days.
Shares of Opko Health Inc. (NYSE:OPK) ended Friday session in red amid volatile trading. The shares closed down -0.02 points or -0.21% at $9.73 with 2.84 million shares getting traded. Post opening the session at $9.73, the shares hit an intraday low of $9.56 and an intraday high of $9.85 and the price vacillated in this range throughout the day. The company has a market cap of $5.30 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) announced that it will release operating and financial results for the three months ended March 31, 2016, after the close of the U.S. financial markets on Monday, May 9, 2016.
OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, May 9, 2016.
The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, May 9, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 2590322
For those unable to participate in the conference call or webcast, a replay will be available beginning May 9, 2016 at 7:30 p.m. ET until May 15, 2016 at 11:59 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 2590322.
The replay can also be accessed for a period of time on OPKO’s website at www.opko.com.